Table 3.

Prognoses according to JIS, ALBI-T, and mALBI-T in training and validation cohorts

JIS score	Score 0	Score 1	Score 2	Score 3	Score 4	Score 5
Training	9.6 (7.3–11.8)	6.9 (6.2–7.7)	3.5 (3.2–4.3)	1.3 (1.0–1.7)	0.4 (0.3–0.7)	0.09 (0.04–0.18)
Validation	9.7 (8.8–10.6)	6.2 (5.8–6.7)	4.1 (3.7–4.3)	1.7 (1.6–2.0)	0.5 (0.4–0.7)	0.1 (0.1–0.2)

ALBI-T score	Score 0	Score 1	Score 2	Score 3	Score 4	Score 5
Training	11.8 (10.2–14.5)	7.1 (6.5–8.4)	5.1 (4.6–5.6)	2.5 (2.1–2.8)	0.6 (0.4–0.9)	0.13 (0.08–0.29)
Validation	11.9 (10.0–13.9)	7.2 (6.7–7.8)	4.8 (4.5–5.2)	2.9 (2.7–3.2)	0.8 (0.7–1.0)	0.2 (0.17–0.3)

mALBI-T score	Score 0	Score 1	Score 2	Score 3	Score 4	Score 5	Score 6
Training	11.8 (10.2–14.5)	8.5 (7.1–10.7)	5.6 (4.9–6.2)	3.8 (3.2–4.4)	2.0 (1.6–2.4)	0.4 (0.3–0.8)	0.13 (0.08–0.29)
Validation	11.9 (10.0–13.9)	8.2 (7.4–9.1)	5.2 (4.9–5.6)	3.7 (3.3–4.1)	2.7 (2.4–3.0)	0.2 (0.17–0.3)	0.14 (0.08–0.19)

Values indicate median survival, years (95% CI).

JIS score, Japan integrated scoring; ALBI-T score, albumin-bilirubin (ALBI) grade and tumor-node-metastasis stage of Liver Cancer Study Group of Japan, 6th edition (TNM-LCSGJ 6th); mALBI-T score, modified ALBI and TNM-LCSGJ 6th.